Leukemia 2011 June
... CLL symptoms usually develop over time. Early in the course of the disease, CLL often has little effect on a person’s well-being. Some people with CLL do not have any symptoms. The disease may be suspected because of abnormal results from blood tests that were ordered either as part of an annual phy ...
... CLL symptoms usually develop over time. Early in the course of the disease, CLL often has little effect on a person’s well-being. Some people with CLL do not have any symptoms. The disease may be suspected because of abnormal results from blood tests that were ordered either as part of an annual phy ...
1 Phase I clinical trial of Mixed Bacterial Vaccine (Coley`s Toxins) in
... Hessen/Germany. Twelve patients with NY-ESO-1 expressing tumors or NY-ESO-1 serum antibodies were enrolled to receive MBV subcutaneously at a starting dose of 250 EU twice weekly. In the absence of a dose-limiting toxicity, the MBV dose was escalated in each patient to the MBV dose level that elicit ...
... Hessen/Germany. Twelve patients with NY-ESO-1 expressing tumors or NY-ESO-1 serum antibodies were enrolled to receive MBV subcutaneously at a starting dose of 250 EU twice weekly. In the absence of a dose-limiting toxicity, the MBV dose was escalated in each patient to the MBV dose level that elicit ...
... findings indistinguishable from idiopathic UC, so microbiologic studies for bacterial (including specific assays for E. coli 0157:H7) and parasitic infection, as well as serologic testing for amoeba when clinical suspicion is high, should be performed in each new patient, and should be considered in ...
February 2010 ACR Bulletin - American College of Radiology
... control, greatly reducing the number of subjects who must be studied. Also, the U.S. FDA accepts evidence of an oncolytic effect as sufficient proof of efficacy for the approval of cancer drugs, thereby avoiding lengthy clinical trials that use death as the endpoint. In essence, clinical trials with ...
... control, greatly reducing the number of subjects who must be studied. Also, the U.S. FDA accepts evidence of an oncolytic effect as sufficient proof of efficacy for the approval of cancer drugs, thereby avoiding lengthy clinical trials that use death as the endpoint. In essence, clinical trials with ...
Guide to Good Prescribing - World Health Organization
... in clinical practice the reverse approach has to be taken, from the diagnosis to the drug. Moreover, patients vary in age, gender, size and sociocultural characteristics, all of which may affect treatment choices. Patients also have their own perception of appropriate treatment, and should be fully ...
... in clinical practice the reverse approach has to be taken, from the diagnosis to the drug. Moreover, patients vary in age, gender, size and sociocultural characteristics, all of which may affect treatment choices. Patients also have their own perception of appropriate treatment, and should be fully ...
Age Related Macular Degeneration ALL INDIA OPHTHALMOLOGICAL SOCIETY B. L. Sujata Rathod
... macular degeneration , in females was 2.5 times increased risk (95% confidence interval 1.01-6.20) compared with those who are ex smokers or never smokers. For males it was 3.2 (95% confidence interval 1.03- 10.50). The Eye Case Control Group also found smoking increases the risk of the exudative ty ...
... macular degeneration , in females was 2.5 times increased risk (95% confidence interval 1.01-6.20) compared with those who are ex smokers or never smokers. For males it was 3.2 (95% confidence interval 1.03- 10.50). The Eye Case Control Group also found smoking increases the risk of the exudative ty ...
Premature ovarian failure: Think `autoimmune disorder`
... 230 Sexuality, Reproduction & Menopause ...
... 230 Sexuality, Reproduction & Menopause ...
Assessing, managing and monitoring biologic therapies for
... Innovation in treatment regimens are progressing, not only in relation to the way biologic therapies are utilised. For example, the early use of non-biologic disease modifying drugs (DMARDs) as a first-line treatment for patients with rheumatoid arthritis, ideally within three months of the onset of ...
... Innovation in treatment regimens are progressing, not only in relation to the way biologic therapies are utilised. For example, the early use of non-biologic disease modifying drugs (DMARDs) as a first-line treatment for patients with rheumatoid arthritis, ideally within three months of the onset of ...
RBR 54(3) - Arquivo-livro (online).indb
... addition to approve the manuscript object of the submission, the authorship and the order of authors listed. It must be signed by all authors. Below is presented an example. Dear Editor, We, the undersigned, declare that this manuscript is original, has not been published before and is not currently ...
... addition to approve the manuscript object of the submission, the authorship and the order of authors listed. It must be signed by all authors. Below is presented an example. Dear Editor, We, the undersigned, declare that this manuscript is original, has not been published before and is not currently ...
Diapositive 1 - The European Respiratory Society
... • Adverse events are frequent and may be severe • Treatment of adverse events means – in the best of cases – the use of further drugs (if available) or interruption of treatment ...
... • Adverse events are frequent and may be severe • Treatment of adverse events means – in the best of cases – the use of further drugs (if available) or interruption of treatment ...
View/Open - UoN Repository
... disorders have been many. There have been concerted efforts to halt or reverse the degenerative process by means of various biological therapies, although these are still in experimental stages1. Currently, the treatment of degenerative spinal diseases remains focused on dealing with symptoms, using ...
... disorders have been many. There have been concerted efforts to halt or reverse the degenerative process by means of various biological therapies, although these are still in experimental stages1. Currently, the treatment of degenerative spinal diseases remains focused on dealing with symptoms, using ...
The use of low-dose naltrexone (LDN) as a novel anti
... (OGFr) [32], are being discovered, raising even more potential mechanisms of action. Given the multiple and varied sites where naltrexone exhibits significant pharmacologic activity, it will be difficult to determine with certainty the paths that are critical for the clinically beneficial effects. T ...
... (OGFr) [32], are being discovered, raising even more potential mechanisms of action. Given the multiple and varied sites where naltrexone exhibits significant pharmacologic activity, it will be difficult to determine with certainty the paths that are critical for the clinically beneficial effects. T ...
Negative impacts of unreported COPD exacerbations on health-related quality of W. Xu*
... patients who had different types of exacerbation and the mean change in HRQoL for patients who had no exacerbation. In order to estimate and control for the potential impact of exacerbations that occurred at the end of the study, patients who had experienced at least one exacerbation (regardless of ...
... patients who had different types of exacerbation and the mean change in HRQoL for patients who had no exacerbation. In order to estimate and control for the potential impact of exacerbations that occurred at the end of the study, patients who had experienced at least one exacerbation (regardless of ...
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing
... complicated ulcers, occur in one of every 20 NSAID users and in one of seven older adults using NSAIDs (19), accounting for 30% of UGIE-related hospitalizations and deaths (20–22). Dyspepsia, defined as upper abdominal pain or discomfort, may occur in individuals taking NSAIDs, including ASA. Dyspep ...
... complicated ulcers, occur in one of every 20 NSAID users and in one of seven older adults using NSAIDs (19), accounting for 30% of UGIE-related hospitalizations and deaths (20–22). Dyspepsia, defined as upper abdominal pain or discomfort, may occur in individuals taking NSAIDs, including ASA. Dyspep ...
2013 - August - World Allergy Organization
... Diagnostic pitfalls of conventional tests (skin testing and serum sIgE testing): (i) inaccurate to screen general population for venom allergy (limited negative and positive predictive value); (ii) levels of sIgE [skin or serum testing] do not correlate with severity of reactions; (iii) up to 30% of ...
... Diagnostic pitfalls of conventional tests (skin testing and serum sIgE testing): (i) inaccurate to screen general population for venom allergy (limited negative and positive predictive value); (ii) levels of sIgE [skin or serum testing] do not correlate with severity of reactions; (iii) up to 30% of ...
Klebsiella pneumoniae 간농양에 병발한 기종성 전립선염 Infection & Chemotherapy
... prostatic tissue, gas and a pus-like discharge mixed with blood were observed by resectoscopy. Some of the infected prostatic tissue was cultured. However, the postoperative bleeding control failed and the patient’s hypovolemic shock persisted, which then ...
... prostatic tissue, gas and a pus-like discharge mixed with blood were observed by resectoscopy. Some of the infected prostatic tissue was cultured. However, the postoperative bleeding control failed and the patient’s hypovolemic shock persisted, which then ...
Microscopic colitis: an unfamiliar but treatable disease
... 50 mg once daily for two weeks. By comparison, only one of the three patients treated with a placebo showed improvement. However, this was not statistically significant in this small study.26 The significant disadvantage of systemic steroids is the well-known side-effect profile, which does not seem ...
... 50 mg once daily for two weeks. By comparison, only one of the three patients treated with a placebo showed improvement. However, this was not statistically significant in this small study.26 The significant disadvantage of systemic steroids is the well-known side-effect profile, which does not seem ...
Pipexus Prolonged-release tablet ENG SmPC
... were mild to moderate, they usually start early in therapy and most tended to disappear even as therapy was continued. Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: v ...
... were mild to moderate, they usually start early in therapy and most tended to disappear even as therapy was continued. Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: v ...
EPAR - Assessment Report - Variation - EMA
... orthopedic surgery to address deformities. Early trials with several different medical therapies were unsuccessful, including those involving fluoride, magnesium, calcitonin, and anabolic steroids. The most promising long-term results have come from studies using intravenous pamidronate. An observat ...
... orthopedic surgery to address deformities. Early trials with several different medical therapies were unsuccessful, including those involving fluoride, magnesium, calcitonin, and anabolic steroids. The most promising long-term results have come from studies using intravenous pamidronate. An observat ...
Pruritus and logical management
... underlies pruritus, patients may have normal-appearing skin or secondary lesions, such as excoriations, prurigo nodules, lichen simplex chronicus, or signs of a secondary bacterial infection. Patients may have the butterfly sign, which is an area of relative hypopigmentation or normal skin on the mi ...
... underlies pruritus, patients may have normal-appearing skin or secondary lesions, such as excoriations, prurigo nodules, lichen simplex chronicus, or signs of a secondary bacterial infection. Patients may have the butterfly sign, which is an area of relative hypopigmentation or normal skin on the mi ...
Clinical Policy Bulletin: Clotting Factors
... antibodies and platelet refractoriness. The EMEA analyzed the efficacy data for persons with anti-glycoprotein IIb/ anti-HLA antibodies and platelet refractoriness. Seventeen patients with from the International Registry and 2 patie independently published case reports were identified, with a total ...
... antibodies and platelet refractoriness. The EMEA analyzed the efficacy data for persons with anti-glycoprotein IIb/ anti-HLA antibodies and platelet refractoriness. Seventeen patients with from the International Registry and 2 patie independently published case reports were identified, with a total ...
- American Journal of Medicine, The
... cardiovascular disease, anemia, and metabolic acidosis, as well as mineral and bone disorder. Prevention of CKD progression requires blood pressure <140/90 mm Hg, use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for patients with albuminuria and hypertension, hemoglob ...
... cardiovascular disease, anemia, and metabolic acidosis, as well as mineral and bone disorder. Prevention of CKD progression requires blood pressure <140/90 mm Hg, use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for patients with albuminuria and hypertension, hemoglob ...
injectable implant instructions for use
... with injectable materials should be followed. • Patients who are using medications that can prolong bleeding, such as aspirin or warfarin, may, as with any injection, experience increased bruising or bleeding at the injection site. • If laser treatment, chemical peeling, or any other procedure bas ...
... with injectable materials should be followed. • Patients who are using medications that can prolong bleeding, such as aspirin or warfarin, may, as with any injection, experience increased bruising or bleeding at the injection site. • If laser treatment, chemical peeling, or any other procedure bas ...